Safety and Preliminary Efficacy of NXL-001 in Patients With Ischemic Stroke | MicrobiomeTrials← Back to trialsNCT06761183
Safety and Preliminary Efficacy of NXL-001 in Patients With Ischemic Stroke
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2025-01-31Est. Completion: 2027-12-31
Enrollment target: 9 participants Locations- Beijing Tiantan Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Atrial Fibrillation (AF)
The goal of this clinical trial is to learn if the cardiac pulsed field ablation system, composed of the cardiac pulsed …
Multiple LocationsEst. completion Mar 2028
Arteriosclerosis Obliterans
This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome …
Guangzhou, ChinaEst. completion Jul 2027
Intracerebral Hemorrhage
Stroke
Stroke, Acute
Stroke, Ischemic
Stroke Hemorrhagic
Stroke (CVA) or TIA
Brain Diseases
Background Reperfusion therapies, i.e., intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT), are most …
Hong Kong, Hong KongEst. completion Dec 31, 2027